Implant Therapy Articles & Analysis
29 news found
The procedure marks the first U.S. patient implant in Synchron’s COMMAND trial, which is being conducted under the first investigational device exemption (IDE) awarded by the FDA to a company assessing a permanently implanted BCI. ...
I am eager to bring my experience to Synchron to help support its mission of developing an endovascular implant that can transfer information from every corner of the brain at ...
MINNEAPOLIS, June 10, 2021 - CVRx©. developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF). announced the completion of the first clinical procedure with the company's new lead implantation approach. The novel ultrasound-guided technique is the latest advancement of CVRx's Barostim™ Baroreflex Activation ...
ByCVRx
“Our recent results presented at the American Academy of Neurology Conference 2022 show that our permanent BCI implant is safe, and can improve independence and quality of life for those living with ...
The device also stayed in place for all four patients and the blood vessel in which the device was implanted remained open. Following implantation in the SWITCH clinical trial, patients were able to use the Stentrode system unsupervised in their homes to send text messages, conduct online shopping and manage their finances. About the Stentrode Synchron’s ...
Four Patients With ALS Who Received Stentrode™ Implant Gained Ability to Perform Daily Online Tasks No Serious Adverse Events Reported after 12 Months Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ device, a ...
For 135 “favorable” patients treated with Cesium-131 implant alone (excluding 12 patients who were treated with external beam radiation therapy and Cesium-131 implant), the outcome was 98.1%. ...
Clinical trials of the device in patients with DRE have shown impressive results comparable to those achieved with adjunctive pharmaceutical and implantable device therapies,” commented Dr. Colin Kealey, President of NeuroSigma. “This Breakthrough Device Designation will expedite completion of a pivotal trial of external trigeminal nerve stimulation ...
Synchron is the only company to receive FDA approval to conduct clinical trials of a permanently implanted BCI. The company’s novel BCI technology leverages the blood vessels as the natural highways to the brain. ...
Statistically significant and clinically meaningful mean change in diurnal IOP at 12 and 26 weeks (p<0.001). Implant persistence through a minimum of 21 weeks with full implant biodegradation by week 40, over a 4-6 week period. Low dose implant shown to be generally well tolerated with no ocular serious adverse events related to product, no ...
Ondrej Choutka, MD, a neurosurgeon, and Lindsay Sales, MD, a radiation oncologist at Saint Alphonsus Regional Medical Center in Boise, have become the first doctors in the Pacific Northwest to utilize a new treatment for brain tumors. They implanted the FDA-cleared GammaTile therapy in a 44-year-old patient with a malignant brain tumor. ...
Technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Study will examine the safety and efficacy of ZetaMetTM in the treatment of metastatic bone lesions as part of advanced stage cancer therapy Study is targeting Stage 4 breast cancer patients who have metastatic lesions in their spinal vertebrae Zetagen ...
The Promaxo system reinforces our practice goals as it not only allows us to refine our biopsies, but also facilitates MR-guided therapies within the comfort of our offices and ambulatory surgery center. ...
Synchron, a brain computer interface company, today announced a Twitter takeover by Philip O’Keefe, one of the patients implanted with the Stentrode brain computer interface. Mr. O’Keefe is the first person to successfully message the world on social media directly through thought using an implantable brain computer interface. ...
The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions The Company is targeting its first human clinical trial for metastatic bone lesions to begin in early 2022 Zetagen Therapeutics, ...
Procedure removes risk of kidney injury or complications in patients with advanced kidney disease or allergy to contrast dye On Sept. 30, CentraCare completed the world’s first contrast-free WATCHMAN implant using 4D holographic therapy guidance, developed by EchoPixel, as the alternative imaging modality. ...
Mehee Choi, director of Medical Affairs at GT Medical Technologies, will discuss new data in patients with recurrent glioblastoma (GBM), and access-to-care for patients with resectable brain tumors. GammaTile is an implantable radiation therapy consisting of bioresorbable collagen tiles embedded with Cesium-131 sources provided by Isoray, Inc. ...
Patients begin using the device at home soon after implantation and may wirelessly control external devices by thinking about moving their limbs. ...
Active Implants, LLC, a developer of orthopedic implant solutions for joint preservation, today announced two-year results of the MERCURY study, which showed that the company’s NUsurface® Meniscus Implant provides statistically superior pain relief beginning at six months compared to non-surgical therapy. ...
ZetaMet™ is a synthetic, small-molecule, inductive biologic, delivered via a drug-eluting implant on an osteopromotive carrier. The European patent follows the previously issued Australian Patent. ...